secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2022-12-22T23:59:59+00:00
Accession:  0001193125-22-311072
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ completes $16.6B acquisition of Abiomed; $380/sh + CVR up to $35/sh
-----------------------------------------------------------------------

- Tender offer expired with ~57.1% of shares tendered; all conditions satisfied.
- Abiomed will operate as a standalone business within JNJ's MedTech segment.
- Transaction expected slightly dilutive to neutral to adjusted EPS in year one, accretive by $0.05 in 2024.
- Abiomed common stock ceased trading on NASDAQ upon completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000119312522311072/0001193125-22-311072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000119312522311072/d428734d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-311072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer